Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate for chronic inflammation control in adults with sickle cell disease
RBR-2s9xvnPhase 2Completed
- Sponsor
- Centro Infantil Boldrini
- Start
- Dec 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate in sickle cell disease (SCD), sponsored by Centro Infantil Boldrini. Started Dec 2014; status: completed.
02
Drugs
methotrexate
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on RBR-2s9xvn.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2s9xvn.